Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + talazoparib
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Sacituzumab govitecan + talazoparib is a combination therapy being investigated for metastatic triple-negative breast cancer (mTNBC). This combination leverages the synergistic effects of two distinct mechanisms: sacituzumab govitecan (SG), an antibody-drug conjugate that delivers the topoisomerase 1 inhibitor SN-38 to cancer cells expressing TROP-2, and talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor. While concurrent administration of these agents caused intolerable myelosuppression, an innovative sequential dosing schedule has shown improved tolerability and preliminary efficacy. The sequential approach involves administering SG on days 1 and 8, followed by talazoparib on days 15-21 of a 21-day cycle, with growth factor prophylaxis required.
- Other names
- SG + talazoparibSG + TZP
02
Targets
TOP1 (DNA Topoisomerase I)Pol II (RNA polymerase II elongation factors)TACSTD2 (Tumor-associated calcium signal transducer 2)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on sacituzumab govitecan + talazoparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + talazoparib.